ClinicalTrials.gg
RecruitingNCT06629363HAMABANKUpdated Oct 22, 2026

Determinants of Malignant Hypertension Onset and Related Target Organ Damages: the HAMA Biobank

An observational study in Malignant Hypertension, sponsored by Centre Hospitalier de PAU. Recruiting at 11 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Centre Hospitalier de PAU · Observational

How we know

From the registry’s dates

  • Started Mar 2026; still recruiting 8 months later.
Updated Oct 22, 2026Now RecruitingFirst site in France+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
1,000
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 211 studies in Hypertension with a site in France — 33 open to participants now, 46 under way, 6 of them phase 3. Hypertension · France.

Planned enrollment
21st of 59
1,000 · median 400
Started
2026
with 8 others
Observational
59 of 211
15 open now
Primary completion
2036-04
later than 45 of 45 live
Registered
192nd of 211
by date

Among the 211 studies in Hypertension with a site in France, this one is the 21st largest by planned enrollment of the 59 observational ones that give a count, is one of 9 that started in 2026, is one of 59 observational ones, reaches primary completion later than 45 of the 45 other live ones, and was the 192nd registered.

Hypertension

6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.

Browse Hypertension studies →

Open to participants now

33 of the 211 studies in Hypertension with a site in France are open now. Recruiting first, the newest first:

27 more — sign in →

All 33 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 211 studies in Hypertension with a site in France, or all of them as a file.
02

Study summary

The HAMA bank is an initiative aimed at collecting, preparing, and storing biological samples from patients treated for malignant hypertension and included in the HAMA cohort. Conducted under CRB (ISO20387) conditions, this biobank serves as an essential resource for understanding the disease's pathophysiology, as well as for identifying novel biomarkers and therapeutic targets

Read the detailed description

Malignant hypertension (MH) is an acute and severe form of hypertension that can lead to rapid target organ damage and potentially be fatal within months if not treated. Despite the severity, MH manifests in various phenotypes, suggesting multiple underlying pathophysiological pathways. The HAMA bank aims to address this by collecting biological samples at two distinct time-points:

For " Pre-existing Patients " in the HAMA cohort: A one-time collection focused on genetic analysis. A full sample (equivalent to sample 1 below) may be collected in option.

For Newly Diagnosed Patients (Incident Patients): Sample 1 "Acute Phase": Collected between Day 0 and Day 7 post-admission to any HAMA recruiting centers. This will be used for initial multi-omics analysis. Sample 2 "Chronic Phase": Collected between the 1st and 6th months during a follow-up visit at the investigating center.

These samples will be cross-referenced with clinical and biological data from the HAMA cohort. The cohort follow-up schedule is: 1, 3, 6, 12 months after MH diagnosis and annually for a total of 5 years.

03

Conditions studied

  • Malignant Hypertension

Keywords

  • Malignant hypertension
  • severe hypertension
  • hypertensive emergency
  • target organ damage
  • pathophysiology
  • biomarkers
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

patients with malignant hypertension

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients included in the HAMA cohort with the following critera :

    • Malignant hypertension according to the classic definition (Severe hypertension associated with severe hypertensive retinopathy)
    • Severe hypertension associated with acute target organ damage due to high blood pressure

Exclusion criteria

Exclusion Criteria:

  • Refusal to participate to the substudy " HAMA bank "
  • patient on chronic dialysis
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
1,000 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • Otherbiobank

    The following samples will be collected : * Serum samples and plasma sample: inclusion visit and follow up visit * Urines samples : inclusion visit and follow up visit * blood DNA: inclusion visit * Blood RNA: inclusion visit and follow up visit

06

What researchers measure

Primary outcomes

  1. Decipher the mechanisms responsible for the transition from severe to malignant hypertension

    Compare the multiomic signature of patients admitted for malignant hypertension, between MHT acute crisis (admission) and resolution (6 month later). Transcriptomic, proteomic and metabolomic evolution between these 2 time points and focus on genetic background in relevant system, like angiogenic, vasoactif system, complement system and inflammasome will be described.

    Time frame: At inclusion and 6 month

Secondary outcomes

  1. Understand the determinants of the heterogeneity in target organs damages (TOD) during MHT crisis

    Patient's multiomic signature according to the number of target organ damage presented by the patients, the presence and severity of each TOD (heart, brain, kidney, retina and endothelium) will be compared

    Time frame: At inclusion

  2. Focus on the role of complement system in MHT crisis

    level of circulating complement factors and transcripts between the admission (acute phase of malignant hypertension) and the follow-up consultation will be specificaly compared. Prevalence of pathogenic variant involved in the complement system in the study population will described.

    Time frame: At inclusion and 6 month

07

Study locations

10 of 11 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2026 (actual). Primary completion is estimated for Apr 2036, 120 months after the start.

Of 348 non-industry observational studies under Hypertension, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 111. This study's planned 120 months is above that.

Counting every sponsor, half of 429 studies reached it within 38 months; a quarter within 17 and three quarters within 96.

Start moved once since we started tracking on Sep 25, 2026: Aug 2025 → Mar 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2024
First posted
Oct 8, 2024
StartActual
Mar 19, 2026was Aug 2025
Primary completionEst.
Apr 1, 2036
CompletionEst.
Apr 1, 2036
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 22, 2026
Sites
11 sites added — first site in France
Show 11 added (11 France)
  • CH d'Annecy · Annecy, France
  • CHU de Bordeaux · Bordeaux, France
  • CH de Chalon sur Saône · Chalon-sur-Saône, France
  • Hospices Civils de Lyon · Lyon, France
  • APHP Avicenne · Paris, France
  • Hôpital Européen Georges Pompidou · Paris, France
  • Hôpital Paris Saint Joseph · Paris, France
  • CHU de Strasbourg · Strasbourg, France
  • CHU de Toulouse · Toulouse, France
  • CHRU de Tours · Tours, France
  • CH de Valenciennes · Valenciennes, France
Oct 22, 2026
Start date
Aug 1, 2025→Mar 19, 2026 (actual)
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Not yet recruiting→Recruiting
    11 sites added — first site in France
    Show 11 added (11 France)
    • CH d'Annecy · Annecy, France
    • CHU de Bordeaux · Bordeaux, France
    • CH de Chalon sur Saône · Chalon-sur-Saône, France
    • Hospices Civils de Lyon · Lyon, France
    • APHP Avicenne · Paris, France
    • Hôpital Européen Georges Pompidou · Paris, France
    • Hôpital Paris Saint Joseph · Paris, France
    • CHU de Strasbourg · Strasbourg, France
    • CHU de Toulouse · Toulouse, France
    • CHRU de Tours · Tours, France
    • CH de Valenciennes · Valenciennes, France
    Start date Aug 1, 2025→Mar 19, 2026 (now actual)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06629363
Lead sponsor
Centre Hospitalier de PAU
Responsible party
Sponsor
First posted
Oct 8, 2024
Start date
Mar 19, 2026
Primary completion
Apr 1, 2036 (estimated)
Completion
Apr 1, 2036 (estimated)
Last update
Oct 22, 2026

Study contacts

Alice SERIS
Contact
alice.seris@ch-pau.fr
0559726997
Romain BOULESTREAU
principal investigator · University Hospital, Bordeaux

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion